Michael P. Murphy, MD
Cryptic Masons Medical Research Foundation Professor of Vascular Biology Research
Professor of Surgery
Adjunct Professor of Anatomy, Cell Biology & Physiology
Adjunct Professor of Microbiology & Immunology
- mipmurph@iu.edu
- Phone
- 317-988-2353
- Address
-
1801 N Senate MPC2 #3500
SVAS
IN
Indianapolis, IN - PubMed:
Bio
Dr. Michael Murphy is a vascular surgeon in Indianapolis, Indiana and is affiliated with multiple hospitals in the area, including Eskenazi Health-Indianapolis and Indiana University Health Medical Center. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice for more than 20 years. He is one of 6 doctors at Eskenazi Health-Indianapolis and one of 7 at Indiana University Health Medical Center who specialize in Vascular Surgery.
Medical Education:
1989 Columbia University, New York, NY
Surgical Training:
1993 Research Fellow, Harvard Medical School, Cardiac Surgery and HeartFailure, Boston,MA
1996 General Surgery Residency, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
1996 Chief Resident, General Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
1997 Assistant to the Surgeon-in-Chief, General Surgery,Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2003 Vascular Surgery Fellowship, Duke University, Durham, NC
Key Publications
Murphy MP, Dalsing MC, Lawson JH, Shafique SS, Klein JH, McKale JM, Abonour RF,Hutchins GD, March KL. Autologous Bone Marrow Mononuclear Cell Therapy is Safe and Promotes Amputation Free Survival in Patients with Critical Limb Ischemia J Vasc Surg 2011; 53: 1565-74.
Sharma AK, Lu G, Jester A, Johnston W, Zhao Y, Hajzus V, Saadatzadeh MR, Su G, Bhamidipati CM, Mehta G, Kron IL, Laubach VE, Murphy MP, and Upchurch GR. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 2012;126: S38-S45.
Prasain, N., Lee, M.R., Vemula, S., Meador, J. L., Yoshimoto, M., Ferkowicz, M.K., Fett, A., Gupta, M., Rapp, B.M., Saadatzadeh, M.R., Ginsberg, M., Elemento, O., Lee, Y., Murphy, M.P., Voytik-Harbin, S.L., Rafii, S., Broxmeyer, H.E., Yoder, M.C., Novel protocol to derive endothelial colony forming cells that display high clonal proliferative potential, extensive replicative capacity, and in vivo vessel forming potential from human pluripotent stem cells. Nat Biotechnol. 2014 Nov; 32(11):1151-7.
Xie J, Jones TJ, Feng D, Cook TG, Jester AA, Babbey CM, March KL, Murphy MP. Human Adipose-Derived Stem Cells Suppress Elastase-induced Murine Abdominal Aortic Inflammation and Aneurysm Expansion through Paracrine Factors. Cell Transplant. 2017 Feb 16;26(2):173-189.
Perin EC, Murphy MP, March KL, et. Al.Cardiovascular Cell Therapy Research Network (CCTRN). Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN Patients with Intermittent Claudication Injected with ALDH Bright Cells (PACE) Trial. Circulation. 2017 Feb 16.
Murphy MP. Ross CR, Kibbe MR. Kelso RL,Sharafuddin MJ, Zeng E, Velazquez O,Laird J, MD and the MOBILE Trial Working Group. A Randomized Evaluation of Autologous Bone Marrow Cell Therapy for Critical Limb Ischemia: Results of the Phase III MOBILE Trial.
Year | Degree | Institution |
---|---|---|
1989 | MD | Columbia University |
1985 | BS | Binghamton College |
Characterizing the Innate and Adaptive Immune Responses in the Pathogenesis of Abdominal Aortic Aneurysm. Our central hypothesis is that the chronic inflammatory process that characterizes AAA initiation and progression is a result of memory T cell sensitization to epitopes produced by lung injury from cigarette exposure. It is when regulatory control is lost that these effector T cells react to similar epitopes (elastin and collagen fragments) in the aortic wall. My laboratory has characterized defects in immune regulation mediated via CD4+CD49b+LAG-3+ Tr1 and Foxp3 T-regulatory cells. Furthermore we have demonstrated that mesenchymal stem cells are capable of inducing Tr1 cells and suppressing AAA expansion in mouse models. Based on these plenary discoveries we are conducting the Phase I ARREST Trial, a first in man analysis of systemic administration of alloegeneic MSCs in patients with small AAA.
Limb ischemia
Carotid Disease
Aortic Aneurysm